Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Efficacy of Dupilumab for Treatment of Moderate-to-Severe Asthma

Pronko, Alexander J., MD; Zappetti, Dana, MD

doi: 10.1097/CPM.0000000000000302
Pulmonary Trends

Synopsis: Dupilumab is a novel biologic agent that targets the shared interleukin 4/13 receptor. It is safe and efficacious in patients with moderate-to-severe asthma; however, subgroup analysis suggests that patients with elevated markers of type-2 inflammation benefit most from this drug.

Source: Castro M, Corren J, Pavord ID, et al. Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. NEJM 2018;378:2486–2496.

Disclosure: The authors declare that they have no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.